Physician profile
Samuel Estes
NPI 1902895295
$3,171.21
in general payments reported to CMS, 2019-2025
21 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $149 · 2021: $467 · 2022: $466 · 2023: $562 · 2024: $661 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $476.57 | 2022-2025 | Miebo, Infuse, Xiidra |
| Johnson & Johnson Vision Care, INC. | $460.60 | 2019-2024 | Acuvue |
| Coopervision INC. | $449.90 | 2019-2024 | Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $439.95 | 2019-2021 | |
| Alcon Vision LLC | $293.43 | 2019-2025 | Precision 1, Total30 |
| Novartis Pharmaceuticals Corporation | $252.26 | 2019-2023 | |
| Oyster Point Pharma, INC. | $128.07 | 2022-2024 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $122.38 | 2022-2025 | |
| Allergan, INC. | $94.04 | 2019-2022 | |
| Biotissue Holdings INC. | $66.13 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $65.52 | 2019-2023 | Cequa |
| Sight Sciences, INC. | $65.00 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $46.00 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $44.49 | 2021 | |
| Dompe US, INC. | $37.92 | 2022-2025 | Oxervate |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis, INC | $35.02 | 2021 | |
| Shire North American Group INC | $27.77 | 2019 | |
| Aerie Pharmaceuticals, INC. | $20.92 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $19.77 | 2020 | |
| Visioneering Technologies, INC. | $13.48 | 2019 | |
| Mallinckrodt Hospital Products INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Estes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.